Skip to main content
. 2022 Sep 12;13:932559. doi: 10.3389/fimmu.2022.932559
CAR chimeric antigen receptor
TA tumor antigen
TAA tumor-associated antigen
BALL B-cell acute lymphoblastic leukemia
FDA Food and Drug Administration
EMA European Medicines Agency
BCMA B-cell maturation antigen
AEMPS Agencia Española del Medicamento y Productos Sanitarios (Spanish drug agency)
scFv single-chain variable fragment
moAb monoclonal antibody
OS osteosarcoma
EGFR epidermal growth factor receptor
FLT3L FMS-like tyrosine kinase 3 ligand
FLT3 FMS-like tyrosine kinase 3
AML acute myeloid leukemia
GM-CSF granulocyte-monocyte colony-stimulating factor
GMR granulocyte-monocyte colony-stimulating factor receptor
JMML juvenile myelomonocytic leukemia
TPO thrombopoietin
MPLR myeloproliferative leukemia receptor
EPHB4 ephrin type-B receptor 4
RMS rhabdomyosarcoma
APRIL a proliferation-inducing ligand
TACI transmembrane activator and calcium-modulator and cyclophilin ligand interactor
MM multiple myeloma
HNSCC head and neck squamous cell carcinoma
10Fn3 10th type III domain of human fibronectin
TNBC triple-negative breast cancer
ITD internal tandem duplication
TKD tyrosine kinase domain
WT wild type
CNS central nervous system
GBM glioblastoma multiforme
GSC stem-like cancer-initiating cell
IL13Ra2 interleukin-13 receptor a2
TK tyrosine kinase
EOC epithelial ovarian cancer
EGF epidermal growth factor
TGF-α transforming growth factor α
CRS cytokine release syndrome
PC plasma cell
PI proteasome inhibitor
IMiD immunomodulatory drug
RRMM relapsed/refractory multiple myeloma
TNF tumor necrosis factor
CAAR chimeric autoantibody receptor
BAR B-cell receptor antigen for reverse targeting
sIg surface immunoglobulin
BCR B-cell receptor
PV pemphigus vulgaris
DLBCL diffuse large B-cell lymphoma
MCL mantle cell lymphoma
CHAR chimeric HLA antibody receptor
DSA donor-specific antibody
HAMA human anti-mouse antibody
VH variable heavy chain
VL variable light chain